查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138355

全球免疫蛋白診斷測試市場2022-2029

Global Immunoprotein Diagnostic Testing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

由於肥胖、類風濕性關節炎、癌症、2 型糖尿病、傳染病和心血管疾病的患病率不斷上升，免疫蛋白診斷測試市場正在增長。

技術進步和肥胖、類風濕性關節炎和癌症患病率的上升預計將推動市場增長。

根據世界衛生組織 (WHO) 的數據，到 2020 年，慢性病將佔全球所有死亡人數的近四分之三，其中 71% 死於缺血性心髒病 (IHD)，75% 死於中風，70糖尿病死亡的百分比預計發生在發展中國家。發展中國家的糖尿病患者人數預計將增加 2.5 倍以上，從 1995 年的 8400 萬增加到 2025 年的 2.28 億。在全球範圍內，估計 60% 的慢性病負擔發生在新興經濟體。事實上，印度和中國發生的心血管疾病仍然比世界上所有經濟發達國家的總和還要多。不僅目前超重和肥胖的患病率已經達到前所未有的水平，而且在大多數發展中地區，這一比例每年都在增加。這種現像對公共衛生的影響是巨大的，並且已經變得顯而易見。因此，慢性病的增加增加了對快速診斷的需求。

不斷增長的老年人口和高發病率正在推動全球免疫蛋白診斷測試市場的增長。此外，對免疫蛋白診斷檢測的需求不斷增長，也可歸因於全球傳染病的流行。不衛生的生活條件，特別是在欠發達地區，也是導致疾病和傳染病的一個因素。出於這個原因，免疫蛋白診斷測試的全球市場正在上升。

預計診斷測試的高成本將阻礙市場增長。

監管框架非常複雜，許多免疫蛋白診斷測試不容易獲得批准，一些診斷測試的高成本可能會阻礙市場增長。

行業分析

全球免疫蛋白診斷測試市場根據波特五力、監管分析、供應鏈分析、定價分析、產品創新和未滿足需求等各種行業因素對市場進行深入分析。

全球免疫蛋白診斷測試市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 技術進步，肥胖、類風濕性關節炎和癌症的患病率增加
    • 限制因素
      • 設備和維護成本高
      • 手術受傷的風險
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析
  • 產品創新
  • 未滿足的需求

第 6 章按測試類型

  • 免疫球蛋白診斷測試
  • C-反應蛋白 (CRP) 診斷試劑
  • 補體系統蛋白診斷劑
  • 免費輕鏈診斷劑
  • 結合珠蛋白診斷劑
  • 前白蛋白診斷劑
  • 其他

第 7 章按應用程序

  • 自身免疫性疾病檢測
  • 傳染病測試
  • 腫瘤學測試
  • 過敏測試
  • 毒理學測試

第 8 章技術

  • 基於□的免疫測定
  • 放射免疫分析
  • 免疫蛋白電泳
  • 化學發光法
  • 免疫熒光檢測
  • 免疫比濁法
  • 其他

第 9 章，最終用戶

  • 醫院和診所
  • 診斷實驗室
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 測試類型基準測試
  • 值得關注的重點公司列表

第 12 章公司簡介

  • Abbott Laboratory
    • 公司概況
    • 測試類型測試類型組合和描述
    • 主要亮點
    • 財務摘要
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Danaher Corporation
  • F. Hoffmann-La Roche Ag
  • Enzo Biochem, Inc
  • Siemens Aktiengesellschaft
  • Ortho Clinical Diagnostics
  • Diasorin S.P.A
  • Abcam Plc

第13章 全球免疫蛋白診斷測試市場-DataM

簡介目錄
Product Code: DMBT2306

Market Overview

Immunoprotein Diagnostic Testing Market size was valued US$ 11,480.26 million in 2021 and is estimated to reach US$ 20,938.71 million by 2029, growing at a CAGR of 7.9% during the forecast period (2022-2029).

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze certain proteins such as immunoglobulin and pre-albumin. With continuous development in technologies, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Market Dynamics

The global immunoprotein diagnostic testing market is growing owing to the rising prevalence of obesity, rheumatoid arthritis, cancer, type 2 diabetes, infectious diseases, and cardiovascular disease.

Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer is expected to drive market growth.

According to the World Health Organization (WHO), it has been projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths are due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. The number of people in the developing world with diabetes will increase by more than 2.5-fold, from 84 million in 1995 to 228 million in 2025. On a global basis, 60% of the burden of chronic diseases will occur in developing countries. Indeed, cardiovascular diseases are even now more numerous in India and China than in all the economically developed countries in the world put together. As for overweight and obesity, not only has the current prevalence already reached unprecedented levels, but the rate at which it is annually increasing in most developing regions is substantial. The public health implications of this phenomenon are staggering and are already becoming apparent. Hence, the rising prevalence of chronic diseases has raised the demand for rapid diagnosis.

The rising geriatric population coupled with an all-time high incidence of chronic diseases has given an impetus to the global market's growth for immunoprotein diagnostic testing. Moreover, the upswing in demand for immunoprotein diagnostic testing can also be attributed to the prevalence of infectious diseases worldwide. Unhygienic living conditions, especially in underdeveloped regions, have also led to diseases and infections. This has brought the global market for immunoprotein diagnostic testing under the spotlight of attention.

High cost of diagnostic tests is expected to hamper the market growth.

The regulatory framework is very complex and doesn't approve many immunoprotein diagnostic tests easily and high cost of some diagnostic tests can hamper the growth of the market.

Industry Analysis

The global Immunoprotein Diagnostic Testing market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Enzyme based immunoassay segment is expected to hold the largest market share in global immunoprotein diagnostic testing market

Based on technology, the immunoprotein diagnostic testing market is segmented into enzyme-based immunoassay, radioimmunoassay, immunoprotein electrophoresis, chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, and others. Among these, enzyme-based immunoassay (EIA) accounted for the largest market share. EIA has used a diagnostic and quality tool in several laboratories and companies. Also, some of the major companies are developing new products with EIA technology. For instance, Abcam offers Human Complement C3 ELISA Kit for diagnosis.

On the other hand, chemiluminescence assay is expected to grow at the highest growth rate during the forecast period, owing to its features such as high sensitivity and specificity, strong ability to detect antigens in human serum & plasma samples. Chemiluminescence assay is an important tool for the instant diagnosis of several diseases and is ascertained to be more accurate than fluorescence-based detection of labeled probes. On November 6th, 2019, ALPCO has launched its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.

Based on application, the immunoprotein diagnostic testing is be segmented into autoimmune disease testing, infectious disease testing, oncology testing, allergy testing, toxicology testing, and endocrine testing. Among these, oncology testing accounted for the largest market share, with rising demand over the forecast period. The presence of various diagnostic methods, such as Epidermal Growth Factor Receptor (EGFR) testing, helps detect mutations in the EFGR gene, which occurs in patients with non-small cell lung cancer, and this helps in treatment planning. In March 2019, NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, launched the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with a triple-negative subtype of breast cancer. This PD-L1 assay is a companion diagnostic test recently approved by the FDA to identify advanced, metastatic triple-negative breast carcinoma cancer patients who may respond to the immune checkpoint inhibitor therapy TECENTRIQ (atezolizumab) used in combination with chemotherapy. TECENTRIQ is the first immunotherapy approved specifically for breast cancer.

Geographical Analysis

North America region holds the largest market share in the global immunoprotein diagnostic testing market

North America is dominating the global immunoprotein diagnostic testing market accounted for the largest market share, owing to rising incidences of chronic diseases, rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year. By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. They account for 81% of hospital admissions, 91% of all prescriptions filled, and 76% of all physician visit. In another instance, the American Cancer Society projected around 1,806,590 new cancer cases and 606,520 cancer deaths in the United States in the year 2020. Because of such a projection, accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

Competitive Landscape

Some of the major players in the immunoprotein diagnostic testing market include F. Hoffmann-La Roche Ag, Abcam PLC, Abbott Laboratories, Diasorin, Enzo Life Sciences, Randox Laboratories, Siemens, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Ortho Clinical Diagnostics, among others.

The key players are adopting various growth strategies such as expansion, mergers & acquisitions, partnerships, product launches, and collaborations contributing to the Immunoprotein Diagnostic Testing market globally. For instance,

  • In July 2019, the U.S. Food and Drug Administration (FDA) cleared for marketing four previously cleared tests with new indications to aid in diagnosing Lyme disease. The tests cleared are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

The Afinion 2: It is an analyser that is a compact, rapid and can perform multi-assay which gives important near patient diagnosis or testing at the point-of-care.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global immunoprotein diagnostic testing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of the device and maintenance
      • 4.1.2.2. Risk of injuries in surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Product Innovations
  • 5.6. Unmet Needs

6. By Test Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
    • 6.1.2. Market Attractiveness Index, By Test Type Segment
  • 6.2. Immunoglobulin Diagnostic Tests
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. C-Reactive Protein (CRP) Diagnostic Tests
  • 6.4. Complement System Proteins Diagnostic Tests
  • 6.5. Free Light Chain Diagnostic Tests
  • 6.6. Haptoglobin Diagnostic Tests
  • 6.7. Prealbumin Diagnostic Tests
  • 6.8. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Autoimmune Disease Testing
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Infectious Disease Testing
  • 7.4. Oncology Testing
  • 7.5. Allergy Testing
  • 7.6. Toxicology Testing

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Enzyme Based Immunoassay
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Radioimmunoassay
  • 8.4. Immunoprotein Electrophoresis
  • 8.5. Chemiluminescence assay
  • 8.6. Immunofluorescence Assay
  • 8.7. Immunoturbidity Assay
  • 8.8. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospital and clinics
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic laboratories
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By S Test Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Test Type Test Types Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Abbott Laboratory
    • 12.1.1. Company Overview
    • 12.1.2. Test Type Test Type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Thermo Fisher Scientific Inc
  • 12.3. Bio-Rad Laboratories, Inc
  • 12.4. Danaher Corporation
  • 12.5. F. Hoffmann-La Roche Ag
  • 12.6. Enzo Biochem, Inc
  • 12.7. Siemens Aktiengesellschaft
  • 12.8. Ortho Clinical Diagnostics
  • 12.9. Diasorin S.P.A
  • 12.10. Abcam Plc

LIST NOT EXHAUSTIVE

13. Global Immunoprotein Diagnostic Testing Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and End User
  • 13.3. Contact Us